Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Terlipressin acetate continuous infusion
Terlipressin continuous infusion · 1 trial · 2 indications
Rate of treatment emergent adverse events assessed by physical examination and laboratory safety
Serial sampling for determination of Terlipressin concentration and metabolite 8-lysine vasopressin in plasma at steady state (Css)
| Arm | Type | Description |
|---|---|---|
| Terlipressin acetate continuous infusion | EXPERIMENTAL | Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days |
| Name | Type | Description |
|---|---|---|
| Terlipressin acetate continuous infusion | DRUG | Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days |
Inclusion Criteria: * Patients with cirrhosis and refractory ascites who required 3 or more large volume (4 liters and more) paracenteses in the previous 60 days Exclusion Criteria: * Ascites with causes other than cirrhosis such as nephrogenic ascites or malignant ascites due to peritoneal carci...
Terlipressin continuous infusion is an investigational small molecule being developed by BioVie Inc. (BIVI) for cirrhosis. It is a continuous infusion formulation of terlipressin, also known as terlipressin acetate continuous infusion. The drug is in Phase 2 clinical development and has been studied in patients with cirrhosis and refractory ascites.
Terlipressin continuous infusion is being studied for use in patients with cirrhosis, specifically those with refractory ascites. It is not approved for this use and remains investigational. The Phase 2 trial evaluated its use in adults with cirrhosis and ascites hepatic.
Terlipressin continuous infusion targets the vasopressin receptors AVPR1A, AVPR1B, and AVPR2. It is classified as a binding agent. By acting on these receptors, it is thought to affect vascular tone and fluid regulation, which is relevant in cirrhosis with ascites.
Terlipressin continuous infusion is being developed by BioVie Inc., which trades under the ticker BIVI. BioVie is the sponsor of the clinical program investigating this formulation for cirrhosis.
Terlipressin continuous infusion is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. The Phase 2 trial has been completed.
Terlipressin continuous infusion has been studied in one completed Phase 2 trial, NCT03107091, titled Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites. The trial enrolled 6 participants in the United States and was uncontrolled, non-randomized, and not double-blind.
Yes, terlipressin continuous infusion is also known as terlipressin acetate continuous infusion. Both names refer to the same investigational product being developed by BioVie Inc. for cirrhosis.